急性心肌梗死患者神经内分泌抑制剂的应用分析  

Analysis of use of neuroendocrine inhibitors in patients with acute myocardial infarction

作　　者：谢诚[1] 高杰[1] 缪丽燕[1] 

机构地区：[1]苏州大学附属第一医院药学部,江苏苏州215006

出　　处：《中国新药与临床杂志》2015年第2期152-155,共4页Chinese Journal of New Drugs and Clinical Remedies

摘　　要：目的了解本院急性心肌梗死患者神经内分泌抑制剂包括肾上腺素β受体阻滞药、血管紧张素转化酶抑制药(ACEI)/血管紧张素Ⅱ受体拮抗药(ARB)和醛固酮受体拮抗药(MRA)的应用现状。方法回顾性收集2012年7月—2014年3月入住本院心血管内科的急性心肌梗死患者105例,对其住院期间及出院带药时上述药物的使用情况进行分析。结果 105例急性心肌梗死患者住院期间神经内分泌抑制剂的使用率为89%,其中联合用药率为64%。93例使用神经内分泌抑制剂的患者中起始选择联合治疗的比例为48%。β受体阻滞药、ACEI/ARB和MRA的剂量达标率分别为32%、52%和100%。结论本院急性心肌梗死患者神经内分泌抑制剂的使用基本合理,但与指南尚有一定差距,应进一步规范其临床应用。AIM To investigate the use of neuroendocrine inhibitors, including 13-blocker, angiotensin converting enzyme inhibitor （ACEI） /angiotensin Ⅱ receptor blocker （ARB） and aldosterone receptor antagonist （MRA） in patients with acute myocardial infarction. METHODS Clinical data of 105 cases and the use of above medicines during hospitalization and discharge were collected from July 2012 to March 2014. RESULTS The use rate of neuroendocrine inhibitors was 89%, with 64% of cases accepting combination therapy. 48% of patients were received multi-neuroendocrine inhibitors as the initial therapeutic regimen. The rates of reaching standard dose of 13-blockers, ACEI/ABR and MRA were 32%, 52% and 100%. CONCLUSION The use of neuroendocrine inhibitors in patients with acute myocardial infarction was basically reasonable, but there was still a certain gap between clinical practice and guideline, and needs further standardization.

关 键 词：心肌梗死 肾上腺素能Β受体拮抗剂 血管紧张素转化酶抑制药 血管紧张素Ⅱ1型受体拮抗药 受体 醛固酮 

分 类 号：R972.4[医药卫生—药品]